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In recent years it has become evident that gap junctions and hemichannels, in concert with extra-
cellular ATP and purinergic receptors, play key roles in several physiological processes and patholog-
ical conditions. However, only recently has their importance in infectious diseases been explored,
likely because early reports indicated that connexin containing channels were completely inacti-
vated under inﬂammatory conditions, and therefore no further research was performed. However,
recent evidence indicates that several infectious agents take advantage of these communication sys-
tems to enhance inﬂammation and apoptosis, as well as to participate in the infectious cycle of sev-
eral pathogens. In the current review, we will discuss the role of these channels/receptors in the
pathogenesis of several infectious diseases and the possibilities of generating novel therapeutic
approaches to reduce or prevent these diseases.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction receptors (purinergic P X). Adenosine receptors, also named P1Gap junction (GJ) channels are formed by the docking of two
hemichannels, each contributed by one cell. Hemichannels consist
of hexamers of homologous subunit proteins, termed connexins
(Cxs), that connect the cytoplasm of adjacent cells [1,2]. In addi-
tion, it was shown that unopposed hemichannels (uHC), before
their cell-to-cell docking to form GJ, are also open on cell surface,
allowing exchange of small factors between the cytoplasm and
the extracellular environment. In addition to the connexin family,
pannexin also can form uHCs. Both types of channels, GJ and uHC
(connexin and pannexin containing), have an internal pore of
approximately 12 Ao, allowing ions and intracellular messengers
up to 1 kDa in molecular mass to diffuse between connected cells
or from the cytoplasm into the extracellular space [1,2]. The diffu-
sion of these second messengers results in the coordination of mul-
tiple physiological functions [2].
ATP is a second messenger exchanged by GJ and uHC and is the
main purinergic messenger. ATP is released into the extracellular
space as a neurotransmitter, but also in conditions of apoptosis
and inﬂammation by exocytosis, transporters, and opening of
uHC. Once released into the extracellular space, ATP binds to puri-
nergic receptors and is degraded by ectonucleotidases to produce
ADP, AMP, and adenosine. These molecules activate speciﬁc puri-
nergic and adenosine receptors. Purinergic receptors are divided
into metabotropic (adenosine and purinergic P2Y) and ionotropic2
receptors, are seven transmembrane metabotropic receptors
coupled to Gi, Gs and Go proteins. P2 receptors are divided into
P2X and P2Y receptors and are activated by ATP, ADP, and UTP.
P2X receptors are ATP – gated cationic channels and are associated
with uHC that upon opening provide the source of intracellular ATP
for purinergic receptor activation. P2Y receptors are activated by
ATP, ADP, UTP, and UDP, and several subtypes of these receptors
work together with uHC providing/releasing ATP as a ligand.
Here, we will review the mechanism by which GJ and uHC in
concert with purinergic receptors and extracellular ATP (or
subproduct of its degradation) participate in several infectious
diseases and on the potential of these channels to be used as
therapeutic targets to reduce or prevent infectious diseases.
2. Inﬂammation and down regulation of Connexin containing
channels: historic perspective
Several publications in the 1990s demonstrated that LPS and
inﬂammation decreased gap junctional communication (GJC) and
Cx expression in liver and heart [3–8]. In addition, experiments
in brain associated damage such as ischemia/reperfusion, cancer
and inﬂammatory diseases, also indicated that inﬂammation/
damage reduced GJC and Cx expression [9,10]. In agreement,
recent... reports examining several pathogens including Bordetella
pertussis, Helicobacter pylori, and several viruses also supported
the idea that infection with several pathogens resulted in the total
shutdown of Cx mediated communication [11]. However, at the
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creased expression of Cx43 in inﬂammatory conditions in liver, kid-
ney and lungs [12–15], suggesting that not all Cxs were affected
equally by inﬂammation/damage. Later studies indicated that Cxs
are expressed in leukocytes [13], microglia [16–19], polymorpho-
nuclear cells [20], monocyte/macrophages [21], T cells [22], and
Kupffer cells [14,15] under inﬂammatory conditions to coordinate
inﬂammation and immune response. These observations suggest
that parenchymal Cxs are negatively affected by inﬂammation/
damage, but immune cells that normally do not express Cxs are
prone to express and form functional channels in inﬂammatory
conditions. Only recently, it has been reported that particular
pathogens such as Shigella, Human immunodeﬁciency virus
(HIV), and Pseudomonas aeruginosa use or increased this communi-
cation system to enhance associated inﬂammation or to participate
in the infectious cycle (see review by [11]). Thus, a better under-
standing of the role of these channels and their association with
purinergic receptors and uHC in physiological and pathological
conditions is required.Fig. 1. Proposed mechanism by which pathogens use extracellular ATP, uHC and
purinergic receptor in the context of infectious diseases. Extracellular and intra-
cellular pathogens bind or activate signaling related to these receptors, leading to
ATP release through uHC containing connexin or pannexin proteins. Extracellular
ATP binds to speciﬁc purinergic receptors, activating calcium inﬂux and G coupled
proteins that facilitate intracellular signaling. This signaling participates in inﬂam-
mation and several pathogens life cycles. In addition, upon release of ATP, several
extracellular enzymes degrade ATP into ADP, AMP, and adenosine, which further
activate other purinergic and adenosine receptors that participate in inﬂammation
and pathogenesis.3. Purinergic receptors and hemichannels: working together
in physiological and pathological conditions
Purinergic receptors participate in several physiological events
such as vasodilation, pain, neuroprotection, cell differentiation,
migration, muscle contraction, T cell differentiation, platelet aggre-
gation, inﬂammation, autocrine and paracrine signaling, neuro-
transmission, apoptosis and several immune responses [23]. Due
to their importance in physiological processes, alterations in
expression and function of these receptors result in pathological
conditions, including epilepsy, excessive pain, hypertension, and
several infectious diseases.
Response to infectious agents or inﬂammation can be summa-
rized in several steps including initial damage or infection, release
of chemoattractants, recruitment of leukocytes, transmigration
and subsequent local inﬂammation/clearance of the agent or dam-
aged area. Normally in the blood, erythrocytes circulate in the
periphery to exchange nutrients and oxygen/CO2. In inﬂammatory
conditions, hemodynamics change and circulating white cells
interact with the endothelial surface in a process called margin-
ation. After this change in localization, leukocytes become adher-
ent and start to transmigrate into areas of damage or infection
by traversing the endothelial cells and basement membrane. Dur-
ing all these processes the presence and participation of Cx and
Panx containing channels, extracellular ATP, and purinergic recep-
tors has been described as discussed below.
The role of extracellular ATP, uHC, and purinergic receptors in
inﬂammation and infectious disease has only recently been exam-
ined and recognized. Purinergic receptors and uHC are highly ex-
pressed in immune cells and play a key role in migration as well
as killing of intracellular pathogens. The best examined purinergic
receptor is P2X7 due to its early identiﬁcation and relatively easy
evaluation of gating due its similar pore size as compared to
uHC. P2X7 is widely expressed in hematopoietic and nervous sys-
tems and participates in physiological and pathological processes
in concert with uHC. Opening of both P2X7 and uHC normally is
low to undetectable mainly due to high concentrations of calcium,
magnesium and the lack of inﬂammatory signals (see [11] for an
excellent review about regulation of these channels). However,
upon opening of uHC, intracellular signaling molecules such as
ATP, NADH, PGE2, and ions are released into the extracellular space,
resulting in activation of several surface receptors, including puri-
nergic receptors.
Several infectious agents have evolved to block or overactivate
these communication systems by releasing several enzymes thatmodulate extracellular concentrations of ATP, such as adenylate ki-
nase, ATPase, and 50-nucleotidase [24–27], altering the communi-
cation between uHC and purinergic receptors. Some of these
pathogens are Mycobacterium tuberculosis, Shigella ﬂexneri, Yersinia
enterocolitica, Staphylococcus aureus and several viruses (see details
below). Another mechanism of pathogen escape is by direct regu-
lation of the expression and function of purinergic receptors as de-
scribed for cytomegalovirus, CMV [28]. Lastly, several pathogens
can regulate ATP secretion as described for Plasmodium falciparum
or Plasmodium berghei [29,30]. It has been proposed that the mech-
anism by which the anti-malarial drug, meﬂoquine, works is by
inhibiting the opening of uHC and purinergic receptors [31], alter-
ing infectivity and disease progression, suggesting a key role of
these channels in the pathogenesis of malaria. In addition, several
pathogens such as HIV, CMV, Plasmodium auruginosa, S. aureus and
Escherichia coli, as well as Streptococcus pneumonia, Clostridium, Y.
enterocolitica and S. ﬂexneri use connexin and pannexin containing
channels to spread infection, inﬂammation and toxicity (see details
in [11]). Thus, several potential mechanisms involving the interac-
tion of uHC, ATP and purinergic receptors are ‘‘hijacked’’ by patho-
gens to survive, replicate and enhance inﬂammation (see Fig. 1).
3.1. Cytokine production and inﬂammation
The best described mechanisms of purinergic receptors and
uHC participation in disease progression are described for cellular
migration of immune cells, detection of apoptotic cells, and secre-
tion of inﬂammatory factors. For example, processing and release
of IL-1b and IL-18 is mediated by secretion of ATP, activation of
P2X7, opening of uHC and elevated release of intracellular ATP
[32–36]. In contrast, chronic release of ATP or inﬂammation
activates cells of the monocyte/macrophage lineage to secrete
anti-inﬂammatory cytokines including IL-10 and IL-1b receptor
antagonist to reduce inﬂammation and causes development of a
Th2 response.
As indicated above, a key element in inﬂammation is the syn-
thesis, processing and release of IL-1b. This cytokine is produced
as two isoforms, pro-IL-1a and pro-IL-1b, which are subsequently
cleaved by interleukin-converting enzyme (ICE), also known as
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gens like rhinoviruses evolved to induce IL-1b secretion without a
P2X7 component [37], suggesting that some viruses can skip the
activation of purinergic receptors to trigger inﬂammation. In addi-
tion to this cytokine, IL-18, also known as interferon-c inducing
factor, is also formed by the processing of pro-IL-18 by ICE. As dis-
cussed later on, a P2X7 polymorphism produces signiﬁcantly less
IL-18 when stimulated by ATP, suggesting a key role in immune re-
sponse and inﬂammation. This individual to individual genetic var-
iability, especially in P2X7 receptors, is essential to understanding
differential responses of particular populations to several patho-
gens. In addition, polymorphic changes in uHC have been described
and may contribute to this variability in immune responses. For
example, Cx37 C1019T polymorphism contributes to H. pylori
infection in patients with gastric cancer [38]. These observations
suggest that genetic alterations in these channels and receptors
could alter inﬂammation and susceptibility to several infectious
agents.
Inﬂammasome activation requires ATP-purinergic receptors to
trigger shedding of microvesicles [34], TLR-4 activation [39], and
apoptosis [40]. Also, ATP impairs IL-10 expression of soluble and
membrane bound HLA-G Ag in human monocytes [41], suggesting
that ATP or pathogens altering ATP secretion/stability could alter
immune responses mediated by the immunosuppressive activity
of IL-10. ATP also inhibits IL-12 and IL-23 expression in human
dendritic cells by a cAMP dependent mechanism [42], suggesting
that ATP also plays a key role in immunosuppression. In addition,
IL-10 suppresses IL-2 secretion [43] by interfering with CD28
induced activation [44]. Thus, by targeting uHC, extracellular
ATP, and purinergic receptors some pathogens may alter NFAT T
cell activation, resulting in anergy, senescence and apoptosis
[45,46].
Another critical event in inﬂammation and infection is leuko-
cyte migration into areas of damage. Most leukocytes migrate in
response to chemoattractants including chemokines, lipids (e.g.
lysophosphatidylchloline released by apoptotic cells) and nucleo-
tides (e.g. ATP and UTP) [47,48]. Several lines of evidence indicate
that uHC and purinergic receptors participate in these events.
Migration of human monocytes in response to CCL2/MCP-1 across
the blood brain barrier is dependent on Cx43 containing gap junc-
tion channels, but we cannot discard the participation of uHC [21].
Further, Cx43 containing channels and purinergic receptors modu-
late neutrophil recruitment/activation. Subsets of CD4+ T cells ex-
press Cx43 and form functional GJ with macrophages [22,49,50].
MCP-1/CCL2 synthesis and release in rat alveolar and peritoneal
macrophages is P2Y2 dependent [51]. Thus, leukocyte migration
is regulated by purinergic receptors, ATP, and uHC during all stages
of inﬂammation. Our data indicate that several chemokines includ-
ing RANTES, MIPs, and SDF-1 cause transient opening of pannexin-
1 uHC in human leukocytes [52]. We propose that this transient
uHC opening is associated with cellular activation and migration,
but further studies are required to test this hypothesis.
In early apoptosis, release of nucleotides occurs by opening of
pannexin-1 uHC. During later events of apoptosis this channel is
targeted by caspase-3 and -7, proteases that cleave an intracellular
portion of the channel, contributing further to the apoptotic pro-
cess by disrupting the gating of the channel [48,53]. Thus, during
the apoptotic process uHC, ATP, and purinergic receptors partici-
pate as regulators of chemoattraction as well as key regulators of
recognition and clearance of apoptotic cells. In addition, there are
several reports that describe the potential of purinergic receptors
and/or uHC to interact with intracellular adaptor proteins, such
as laminin, actin, actinin, integrins, kinases and phosphatases
[54,55], to amplify inﬂammation and damage but the signiﬁcance
of these interactions is still unclear. All these areas are under active
investigation.3.2. Tuberculosis
M. tuberculosis is the infectious agent that causes tuberculosis in
humans. In this infectious disease, activation of P2X7 receptors play
a key role in inducing intracellular killing of this bacterium inside
of macrophages by a calcium dependent mechanism that induces
phagosome–lysosome fusion [56–58]. This response to mycobacte-
rial infection is dependent on polymorphic changes in the P2X7
receptor [59]. In addition, several splicing variants of P2X7 have
been described as having different agonist dependency and inter-
action with pannexin-1 uHC [60], suggesting that these changes
may also contribute to the pathogenesis of tuberculosis. Pannex-
in-1 uHC also has several genetic isoforms [61], suggesting that
the interaction of this complex between purinergic and uHC is
dependent on the genetic background of each individual, providing
additional risk and protective host factors against tuberculosis.
Further, the allele 1513C of P2X7 is a risk factor in the development
of extrapulmonary and pulmonary tuberculosis in several ethnic
populations, including North Indian, Mexican, Russian, and Turkish
[62]. In contrast, P2X7 polymorphism in position -762 is protective
against tuberculosis in an Asian-Indian cohort [63].
Similar effects of extracellular ATP and purinergic receptors
have been described in clearance and immune response to Chla-
mydia by a phospho-lipase D dependent mechanism, resulting in
70–90% elimination of this intracellular bacterium in macrophages
[64–66]. However, several pathogens can ‘‘hijack’’ these systems.
For example, Chlamydia infected macrophages are protected from
apoptosis while uninfected cells are still susceptible to cell death
[65]. Similar survival mechanisms were observed in HIV infected
cells to generate reservoirs to perpetuate replication and pathogen
survival [67–69].
3.3. Shigella and Yersinia
These are gram negative bacteria that are transmittedmainly by
the fecal-oral route, resulting in diarrhea and fever by a mecha-
nism involving invasion and replication in the colon with epithelial
dysfunction. Infection of epithelial cells with S. ﬂexneri results in
Cx43, 32 and 26 uHC activity that supports invasion, by actin
and PLC dependent mechanisms [70], resulting in ATP release that
helps bacterial invasion and replication [70,71]. In addition, in-
fected cells induce a bystander activation of uninfected cells result-
ing in secretion of IL-18 by a gap junction dependent mechanism
[72]. It is critical to mention that secretion of IL-18 is also depen-
dent on purinergic receptor activation as described above. Interest-
ingly, the mechanism of S. ﬂexneri uptake was dependent on
micropodial extensions from the cell surface (like ﬁlopodium)
allowing complexes of proteins in the tips of these processes to
attach the bacteria by an ATP and Cx dependent mechanism. This
local release of ATP activates Erk1/2 and results in actin retrograde
ﬂow of these processes that are in contact with the bacteria. In
cases of infection with Y. enterocolitica, opening of Cx43 uHC
has been described by a mechanism dependent on channel
phosphorylation [73]. Thus, both entero-pathogens utilize the
complex interactions of uHC, ATP, and purinergic receptors, as well
as GJ channels to invade, replicate and amplify dysfunction in the
host.
3.4. Staphyloccocus aureus
This gram positive bacterium lives in every healthy human. Due
to the wide use of antibiotics, methicillin resistant S. aureus (MRSA)
has emerged. Mainly found in hospitals and several sensitive
communities, a key pathogenic component of this bacterium is
the peptidoglycan present in the bacterial cell wall. Peptidoglycan
reduces Cx expression (protein and mRNA) and functional gap
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MAPK [74]. Studies in brain slices also demonstrated down regula-
tion of gap junctional communication in response to peptidoglycan
[75]. However, despite the reduction in GJC, increased expression
of Cx43 and Cx30 as well as opening of uHC has been reported
[75,76]. In contrast, peptidoglycan induces expression of Cxs that
result in functional gap junction communication (GJC) in microglia,
suggesting that depending of the cell type and type of the insult,
these channels could participate in both physiological and patho-
logical conditions.
3.5. Cytomegalovirus (CMV)
This usually harmless virus is a double-stranded DNA virus and
member of the herpes virus family. Around 50–80% of the popula-
tion is infected. Viral transmission occurs by contact with saliva,
urine, breast milk and other ﬂuids. 0.2–1.2% of all births are CMV
contaminated and no treatment is available. However, congenital
CMV infection is a major public health problem that results in per-
manent problems such as hearing loss, and mental/developmental
disabilities. It is clear that hearing loss is attributable to congenital
CMV infection and is associated with heterozygote Cx26 mutations
as compared to congenital CMV infected children without hearing
loss [77], suggesting that potential genetic changes induced by
CMV infection may alter Cx26 channels, including uHC and GJ. Fur-
ther, dysfunction of Cx26 uHC, GJ, and purinergic receptors has
been associated with mild to severe hearing/deafness [78,79], sug-
gesting a potential link between both conditions.
CMV infection is a strong promoter of Cx43 degradation and
disruption of GJC [80]. Central and peripheral nervous system
development is highly dependent in Cx43 GJ and perhaps uHC
[81,82], and we propose that CMV infection may compromise this
development [83]. We propose that CMV alters Cx43 trafﬁcking
and function, resulting in CMV associated CNS compromise often
observed in CMV infected children. This is a new area of research
that requires priority due to the signiﬁcant contribution of the
virus to nervous system and hearing problems.
3.6. Other viral and bacterial infections
As indicated above both viral and bacterial infection can reduce
communication between uHC, GJ, purinergic receptors, and alter
secretion of ATP. Swine Inﬂuenza viral infection down-regulates
endothelial Cx43 expression by increased degradation in a ERK
dependent manner [84]. Borna virus also down regulates Cx36 in
speciﬁc CNS cell types [85–87]. Inﬂuenza during pregnancy alters
development of the brain of the fetus, suggesting that viruses can
impact neuronal development by affecting GJs [88] possibly by a
similar mechanism as proposed for CMV. Studies in Vero cells
demonstrated that infection with Herpes Simplex Virus-2 (HSV-
2) and treatment with the antiviral agent, acyclovir, down-regu-
lated GJ channels and Cxs expression [89–91]. It was reported that
an increase in tyrosine phosphorylation by HSV-2 and Rous
sarcoma virus leads to an inhibition of GJ and Cx43 expression
[92–94]. Bovine papillomavirus type 4 E8, when bound to ductin,
causes loss of GJ between primary ﬁbroblasts [95,96]. As indicated
above most viruses reduced communication and expression of
these channels/receptors contributing to inﬂammation and paren-
chymal dysfunction.
3.7. HIV pathogenesis
HIV is a retrovirus that causes acquired immunodeﬁciency
syndrome (AIDS), a condition that mainly attacks the immune
system allowing opportunistic infections, cancer and aging relateddiseases to rise due to lack of an effective immune system.
Normally, HIV infects a variety of immune and non-immune cells,
including CD4+ T cells, macrophages, microglia, and astrocytes.
Our results in HIV CNS infection indicate that Cx containing
channels, gap junctions and uHC, play a key role in ampliﬁcation
of inﬂammation and apoptosis. In the CNS, microglial cell and
perivascular macrophages are the predominant cell types infected
by HIV [97,98]. However, a small population of HIV infected
astrocytes has been detected [98–106]. The importance of these
few infected astrocytes in the pathogenesis of NeuroAIDS has
not been examined extensively. Our data indicates that astrocytes
are minimally infected by HIV (5–8%), but despite this low
infection, HIV uses GJ to spread toxicity and inﬂammation into
uninfected surrounding cells, such as astrocytes and endothelial
cells of the blood brain barrier [107]. The small number of HIV
infected astrocytes resulted in large alterations in glutamate
metabolism and CCL2 secretion, supporting the idea that HIV
infection of astrocytes is essential for neuronal compromise
and leukocyte transmigration, respectively. Interestingly, HIV
infected cells are protected from apoptosis by an unknown
mechanism [67,69,108]. We propose that these surviving cells
generate CNS viral reservoirs within the CNS. We recently
identiﬁed the intracellular signals that mediate these toxic effects
as Cytochrome C dependent molecules, including IP3 and intracel-
lular calcium [67].
In addition, we showed that HIV infection of astrocytes results
in the opening of Cx43 uHC, secretion of ATP, and inﬂammation.
Opening of Cx43 uHC requires interaction of the virus with an un-
known receptor(s) on the membrane of astrocytes. Microarray
analysis indicated that dickkopf-1 protein (DKK1, a soluble wnt
pathway inhibitor) mediates compromise of neuronal processes
in neurons mediated by HIV infection of astrocytes [109]. Previous
to our work, DKK1 also was identiﬁed as a key regulator of IFN-c
enhancement of HIV replication and reactivation in astrocytes
[110], suggesting that DKK1 also plays a role in HIV replication
in astrocytes. The ﬁndings that Cxs participate in the pathogenesis
of NeuroAIDS open a new avenue of investigation to study the
mechanisms by which HIV ‘‘hijacks’’ this communication system,
GJ and uHC, to spread toxicity, inﬂammation, and to increase leu-
kocyte transmigration into the CNS, and may suggest novel thera-
peutic approaches to target NeuroAIDS.
Our data and others indicates that HIV binding to CD4+ T lym-
phocytes and macrophages also results in activation of pannexin-
1 uHC, release of ATP, and activation of speciﬁc purinergic recep-
tors [111–113]. Exposure of CD4+ T lymphocytes to HIV results in
the biphasic opening of pannexin-1 uHC: early (5–15 min) during
the interaction of the virus with CD4 and CCR5 or CXCR4, depend-
ing of the viral strain used and late, during the release of new viri-
ons into the medium (18–24 h). Blocking pannexin-1 uHC totally
abolished viral replication. Experiments in human macrophages
also indicate that HIV infection requires secretion of ATP and acti-
vation of purinergic receptors. We demonstrated that P2X1 recep-
tors are essential for HIV entry into macrophages. However, we
did not identify where in the viral cell cycle, P2X7 and P2Y1 are reg-
ulating replication. In addition, activation of P2Y2 has been also
associated with HIV infection and replication [111].
In contrast, activation of adenosine receptors is protective
against HIV tat induced toxicity of neurons [114,115], suggesting
that adenosine may also play an important role in preventing
HIV-tat neurotoxicity within the CNS. In addition, activation of
adenosine receptors down regulates surface expression of CXCR4
and CCR5 on CD4+ T lymphocytes [116], suggesting that adenosine
is protective against HIV infection. Thus, further studies are re-
quired to design new therapeutic approaches to reduce and block
HIV infection and replication in immune and CNS cells.
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The ﬁndings that uHC containing pannexins or connexins work-
ing in concert with purinergic receptors and extracellular ATP (see
Fig. 1) still is a poorly explored area and requires further investiga-
tion. In addition, it is not surprising that these components are
misused by several pathogens that have evolved to take advantage
of this system to coordinate infection, replication, and associated
inﬂammation. Several pharmaceutical companies already devel-
oped drugs to target several purinergic receptors as well as uHC
(probenecid) for different diseases, including vascular dysfunctions
and arthritis related diseases. However, we still require speciﬁc
agonists and antagonists as well as the identiﬁcation of the mech-
anisms by which pathogens alter these pathways, in order to de-
sign, in an informed manner, novel therapeutic approaches to
reduce the devastating consequences of infectious diseases. In
contrast, several compounds that blocks purinergic receptors are
consumed daily without control as food dyes, including compounds
derivate from brilliant blue G and Brilliant Blue FCF that are present
in several foods and drinks. The consequences of the ingestion of these
blockers is unknown but we can predict that reducing immune activa-
tion and elimination of cancer cells, could results in depressed immune
response and faster cancer evolution amount several potential diseases
affected.
The relatively recent discovery of these complexes between puri-
nergic receptors, extracellular ATP and hemichannels, opens new ave-
nues to understand several diseases with impaired cellular migration,
inﬂammation, and cell clearance (cancer, regeneration and aging). The
implications that several pathogens also ‘‘hijacks’’ these complexes
indicates that targeting these proteins also could prevent and reduce
infectious processes. Thus, the possibility of targeting these complexes
of proteins to prevent and treat infectious diseases emerges as a novel
therapeutic form to treat infectious agents.
Acknowledgments
This work was supported by the National Institutes of Mental
Health Grants, MH096625 (to E.A.E.) and by funding of the Public
Research Institute (PHRI). The authors had no ﬁnancial interest.References
[1] Bennett, M.V., Contreras, J.E., Bukauskas, F.F. and Saez, J.C. (2003) New roles
for astrocytes: gap junction hemichannels have something to communicate.
Trends Neurosci. 26, 610–617.
[2] Saez, J.C., Contreras, J.E., Bukauskas, F.F., Retamal, M.A. and Bennett, M.V.
(2003) Gap junction hemichannels in astrocytes of the CNS. Acta Physiol.
Scand. 179, 9–22.
[3] Fernandez-Cobo, M., Gingalewski, C., Drujan, D. and De Maio, A. (1999)
Downregulation of connexin 43 gene expression in rat heart during
inﬂammation. The role of tumour necrosis factor. Cytokine 11, 216–224.
[4] Gingalewski, C., Wang, K., Clemens, M.G. and De Maio, A. (1996)
Posttranscriptional regulation of connexin 32 expression in liver during
acute inﬂammation. J. Cell Physiol. 166, 461–467.
[5] Theodorakis, N.G. and De Maio, A. (1999) Cx32 mRNA in rat liver: effects of
inﬂammation on poly(A) tail distribution and mRNA degradation. Am. J.
Physiol. 276, R1249–R1257.
[6] Temme, A., Ott, T., Dombrowski, F. and Willecke, K. (2000) The extent of
synchronous initiation and termination of DNA synthesis in regenerating
mouse liver is dependent on connexin32 expressing gap junctions. J. Hepatol.
32, 627–635.
[7] De Maio, A., Gingalewski, C., Theodorakis, N.G. and Clemens, M.G. (2000)
Interruption of hepatic gap junctional communication in the rat during
inﬂammation induced by bacterial lipopolysaccharide. Shock 14, 53–59.
[8] Lidington, D., Tyml, K. and Ouellette, Y. (2002) Lipopolysaccharide-induced
reductions in cellular coupling correlate with tyrosine phosphorylation of
connexin 43. J. Cell Physiol. 193, 373–379.
[9] Rouach, N., Avignone, E., Meme, W., Koulakoff, A., Venance, L., Blomstrand, F.
and Giaume, C. (2002) Gap junctions and connexin expression in the normal
and pathological central nervous system. Biol. Cell 94, 457–475.
[10] Kielian, T. (2008) Glial connexins and gap junctions in CNS inﬂammation and
disease. J. Neurochem. 106, 1000–1016.[11] Ceelen, L., Haesebrouck, F., Vanhaecke, T., Rogiers, V. and Vinken, M. (2011)
Modulation of connexin signaling by bacterial pathogens and their toxins.
Cell. Mol. Life Sci. 68, 3047–3064.
[12] Fernandez-Cobo, M., Gingalewski, C. and De Maio, A. (1998) Expression of the
connexin 43 gene is increased in the kidneys and the lungs of rats injected
with bacterial lipopolysaccharide. Shock 10, 97–102.
[13] Jara, P.I., Boric, M.P. and Saez, J.C. (1995) Leukocytes express connexin 43
after activation with lipopolysaccharide and appear to form gap junctions
with endothelial cells after ischemia-reperfusion. Proc. Natl. Acad. Sci. U.S.A.
92, 7011–7015.
[14] Eugenin, E.A., Gonzalez, H.E., Sanchez, H.A., Branes, M.C. and Saez, J.C. (2007)
Inﬂammatory conditions induce gap junctional communication between rat
Kupffer cells both in vivo and in vitro. Cell Immunol. 247, 103–110.
[15] Gonzalez, H.E., Eugenin, E.A., Garces, G., Solis, N., Pizarro, M., Accatino, L. and
Saez, J.C. (2002) Regulation of hepatic connexins in cholestasis: possible
involvement of Kupffer cells and inﬂammatory mediators. Am. J. Physiol.
Gastrointest. Liver Physiol. 282, G991–G1001.
[16] Dobrenis, K., Chang, H.Y., Pina-Benabou, M.H., Woodroffe, A., Lee, S.C.,
Rozental, R., Spray, D.C. and Scemes, E. (2005) Human and mouse microglia
express connexin36, and functional gap junctions are formed between rodent
microglia and neurons. J. Neurosci. Res. 82, 306–315.
[17] Martinez, A.D., Eugenin, E.A., Branes, M.C., Bennett, M.V. and Saez, J.C. (2002)
Identiﬁcation of second messengers that induce expression of functional gap
junctions in microglia cultured from newborn rats. Brain Res. 943, 191–201.
[18] Eugenin, E.A., Eckardt, D., Theis, M., Willecke, K., Bennett, M.V. and Saez, J.C.
(2001) Microglia at brain stab wounds express connexin 43 and in vitro form
functional gap junctions after treatment with interferon-gamma and tumor
necrosis factor-alpha. Proc. Natl. Acad. Sci. U.S.A. 98, 4190–4195.
[19] Garg, S., Md Syed, M. and Kielian, T. (2005) Staphylococcus aureus-derived
peptidoglycan induces Cx43 expression and functional gap junction
intercellular communication in microglia. J. Neurochem. 95, 475–483.
[20] Branes, M.C., Contreras, J.E. and Saez, J.C. (2002) Activation of human
polymorphonuclear cells induces formation of functional gap junctions and
expression of connexins. Med. Sci. Monit. 8, BR313–BR323.
[21] Eugenin, E.A., Branes, M.C., Berman, J.W. and Saez, J.C. (2003) TNF-alpha plus
IFN-gamma induce connexin43 expression and formation of gap junctions
between human monocytes/macrophages that enhance physiological
responses. J. Immunol. 170, 1320–1328.
[22] Bermudez-Fajardo, A., Yliharsila, M., Evans, W.H., Newby, A.C. and Oviedo-
Orta, E. (2007) CD4+ T lymphocyte subsets express connexin 43 and establish
gap junction channel communication with macrophages in vitro. J. Leukocyte
Biol. 82, 608–612.
[23] Riteau, N. et al. (2012) ATP release and purinergic signaling: a common
pathway for particle-mediated inﬂammasome activation. Cell Death Dis. 3,
e403.
[24] Zaborina, O., Li, X., Cheng, G., Kapatral, V. and Chakrabarty, A.M. (1999)
Secretion of ATP-utilizing enzymes, nucleoside diphosphate kinase and
ATPase, by Mycobacterium bovis BCG: sequestration of ATP from
macrophage P2Z receptors? Mol. Microbiol. 31, 1333–1343.
[25] Punj, V., Zaborina, O., Dhiman, N., Falzari, K., Bagdasarian, M. and
Chakrabarty, A.M. (2000) Phagocytic cell killing mediated by secreted
cytotoxic factors of Vibrio cholerae. Infect. Immun. 68, 4930–4937.
[26] Franchi, L., Kanneganti, T.D., Dubyak, G.R. and Nunez, G. (2007) Differential
requirement of P2X7 receptor and intracellular K+ for caspase-1 activation
induced by intracellular and extracellular bacteria. J. Biol. Chem. 282, 18810–
18818.
[27] Paoletti, A., Raza, S.Q., Voisin, L., Law, F., Pipoli da Fonseca, J., Caillet, M.,
Kroemer, G. and Perfettini, J.L. (2012) Multifaceted roles of purinergic
receptors in viral infection. Microbes Infect. 14, 1278–1283.
[28] Zandberg, M., van Son, W.J., Harmsen, M.C. and Bakker, W.W. (2007) Infection
of human endothelium in vitro by cytomegalovirus causes enhanced
expression of purinergic receptors: a potential virus escape mechanism?
Transplantation 84, 1343–1347.
[29] Levano-Garcia, J., Dluzewski, A.R., Markus, R.P. and Garcia, C.R. (2010)
Purinergic signalling is involved in the malaria parasite Plasmodium
falciparum invasion to red blood cells. Purinergic signalling 6, 365–372.
[30] Tanneur, V. et al. (2006) Purinoceptors are involved in the induction of an
osmolyte permeability in malaria-infected and oxidized human erythrocytes.
FASEB J. 20, 133–135.
[31] Iglesias, R., Locovei, S., Roque, A., Alberto, A.P., Dahl, G., Spray, D.C. and
Scemes, E. (2008) P2X7 receptor–Pannexin1 complex: pharmacology and
signaling. Am. J. Physiol. Cell Physiol. 295, C752–C760.
[32] Ferrari, D., Pizzirani, C., Adinolﬁ, E., Lemoli, R.M., Curti, A., Idzko, M., Panther,
E. and Di Virgilio, F. (2006) The P2X7 receptor: a key player in IL-1 processing
and release. J. Immunol. 176, 3877–3883.
[33] Huang, T.T. et al. (2013) Hirsutella sinensis mycelium suppresses interleukin-
1beta and interleukin-18 secretion by inhibiting both canonical and non-
canonical inﬂammasomes. Sci. Rep. 3, 1374.
[34] Gulinelli, S. et al. (2012) IL-18 associates to microvesicles shed from human
macrophages by a LPS/TLR-4 independent mechanism in response to P2X
receptor stimulation. Eur. J. Immunol. 42, 3334–3345.
[35] Dinarello, C.A. (2007) Interleukin-18 and the pathogenesis of inﬂammatory
diseases. Semin. Nephrol. 27, 98–114.
[36] Bachmann, M., Horn, K., Poleganov, M.A., Paulukat, J., Nold, M., Pfeilschifter, J.
and Muhl, H. (2006) Interleukin-18 secretion and Th1-like cytokine
responses in human peripheral blood mononuclear cells under the
1394 E.A. Eugenin / FEBS Letters 588 (2014) 1389–1395inﬂuence of the toll-like receptor-5 ligand ﬂagellin. Cell Microbiol. 8, 289–
300.
[37] Shi, L., Manthei, D.M., Guadarrama, A.G., Lenertz, L.Y. and Denlinger, L.C.
(2012) Rhinovirus-induced IL-1beta release from bronchial epithelial cells is
independent of functional P2X7. Am. J. Respir. Cell Mol. Biol. 47, 363–371.
[38] Jing, Y.M., Guo, S.X., Zhang, X.P., Sun, A.J., Tao, F. and Qian, H.X. (2012)
Association between C1019T polymorphism in the connexin 37 gene and
Helicobacter pylori infection in patients with gastric cancer. Asian Pac. J.
Cancer Prev. 13, 2363–2367.
[39] Thomas, L.M. and Salter, R.D. (2010) Activation of macrophages by P2X7-
induced microvesicles from myeloid cells is mediated by phospholipids and
is partially dependent on TLR4. J. Immunol. 185, 3740–3749.
[40] Qu, Y. et al. (2011) Pannexin-1 is required for ATP release during apoptosis
but not for inﬂammasome activation. J. Immunol. 186, 6553–6561.
[41] Rizzo, R., Ferrari, D., Melchiorri, L., Stignani, M., Gulinelli, S., Baricordi, O.R.
and Di Virgilio, F. (2009) Extracellular ATP acting at the P2X7 receptor
inhibits secretion of soluble HLA-G from human monocytes. J. Immunol. 183,
4302–4311.
[42] Schnurr, M., Toy, T., Shin, A., Wagner, M., Cebon, J. and Maraskovsky, E. (2005)
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and
enhances IL-23 expression in human dendritic cells: a novel role for the
cAMP pathway. Blood 105, 1582–1589.
[43] Taga, K., Cherney, B. and Tosato, G. (1993) IL-10 inhibits apoptotic cell death
in human T cells starved of IL-2. Int. Immunol. 5, 1599–1608.
[44] Akdis, C.A., Joss, A., Akdis, M., Faith, A. and Blaser, K. (2000) A molecular basis
for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28
tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J.
14, 1666–1668.
[45] Woehrle, T., Yip, L., Manohar, M., Sumi, Y., Yao, Y., Chen, Y. and Junger, W.G.
(2010) Hypertonic stress regulates T cell function via pannexin-1
hemichannels and P2X receptors. J. Leukocyte Biol. 88, 1181–1189.
[46] Woehrle, T., Yip, L., Elkhal, A., Sumi, Y., Chen, Y., Yao, Y., Insel, P.A. and Junger,
W.G. (2010) Pannexin-1 hemichannel-mediated ATP release together with
P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse.
Blood 116, 3475–3484.
[47] Lauber, K. et al. (2003) Apoptotic cells induce migration of phagocytes via
caspase-3-mediated release of a lipid attraction signal. Cell 113, 717–730.
[48] Elliott, M.R. et al. (2009) Nucleotides released by apoptotic cells act as a ﬁnd-
me signal to promote phagocytic clearance. Nature 461, 282–286.
[49] Sarieddine, M.Z., Scheckenbach, K.E., Foglia, B., Maass, K., Garcia, I., Kwak, B.R.
and Chanson, M. (2009) Connexin43 modulates neutrophil recruitment to
the lung. J. Cell Mol. Med. 13, 4560–4570.
[50] Chen, Y. (2010) Purinergic signaling: a fundamental mechanism in neutrophil
activation. Sci. Signaling 3, ra45.
[51] Stokes, L. and Surprenant, A. (2007) Purinergic P2Y2 receptors induce
increased MCP-1/CCL2 synthesis and release from rat alveolar and
peritoneal macrophages. J. Immunol. 179, 6016–6023.
[52] Orellana, J.A., Velasquez, S., Williams, D.W., Saez, J.C., Berman, J.W. and
Eugenin, E.A. (2013) Pannexin1 hemichannels are critical for HIV infection of
human primary CD4+ T lymphocytes. J. Leukocyte Biol. 94, 399–407.
[53] Chekeni, F.B. et al. (2010) Pannexin 1 channels mediate ’ﬁnd-me’ signal
release and membrane permeability during apoptosis. Nature 467, 863–867.
[54] Kim, M., Spelta, V., Sim, J., North, R.A. and Surprenant, A. (2001) Differential
assembly of rat purinergic P2X7 receptor in immune cells of the brain and
periphery. J. Biol. Chem. 276, 23262–23267.
[55] Kim, M., Jiang, L.H., Wilson, H.L., North, R.A. and Surprenant, A. (2001)
Proteomic and functional evidence for a P2X7 receptor signalling complex.
EMBO J. 20, 6347–6358.
[56] Lammas, D.A., Stober, C., Harvey, C.J., Kendrick, N., Panchalingam, S. and
Kumararatne, D.S. (1997) ATP-induced killing of mycobacteria by human
macrophages is mediated by purinergic P2Z(P2X7) receptors. Immunity 7,
433–444.
[57] Fairbairn, I.P., Stober, C.B., Kumararatne, D.S. and Lammas, D.A. (2001) ATP-
mediated killing of intracellular mycobacteria by macrophages is a P2X(7)-
dependent process inducing bacterial death by phagosome–lysosome fusion.
J. Immunol. 167, 3300–3307.
[58] Kusner, D.J. and Barton, J.A. (2001) ATP stimulates human macrophages to
kill intracellular virulent Mycobacterium tuberculosis via calcium-dependent
phagosome–lysosome fusion. J. Immunol. 167, 3308–3315.
[59] Fernando, S.L., Saunders, B.M., Sluyter, R., Skarratt, K.K., Goldberg, H., Marks,
G.B., Wiley, J.S. and Britton, W.J. (2007) A polymorphism in the P2X7 gene
increases susceptibility to extrapulmonary tuberculosis. Am. J. Respir. Crit.
Care Med. 175, 360–366.
[60] Xu, X.J., Boumechache, M., Robinson, L.E., Marschall, V., Gorecki, D.C., Masin,
M. and Murrell-Lagnado, R.D. (2012) Splice variants of the P2X7 receptor
reveal differential agonist dependence and functional coupling with
pannexin-1. J. Cell Sci. 125, 3776–3789.
[61] Li, S., Tomic, M. and Stojilkovic, S.S. (2011) Characterization of novel
Pannexin 1 isoforms from rat pituitary cells and their association with
ATP-gated P2X channels. Gen. Comp. Endocrinol. 174, 202–210.
[62] Miller, C.M., Boulter, N.R., Fuller, S.J., Zakrzewski, A.M., Lees, M.P., Saunders,
B.M., Wiley, J.S. and Smith, N.C. (2011) The role of the P2X(7) receptor in
infectious diseases. PLoS Pathog. 7, e1002212.
[63] Sambasivan, V., Murthy, K.J., Reddy, R., Vijayalakshimi, V. and Hasan, Q.
(2010) P2X7 gene polymorphisms and risk assessment for pulmonary
tuberculosis in Asian Indians. Dis. Markers 28, 43–48.[64] Coutinho-Silva, R., Stahl, L., Raymond, M.N., Jungas, T., Verbeke, P., Burnstock,
G., Darville, T. and Ojcius, D.M. (2003) Inhibition of chlamydial infectious
activity due to P2X7R-dependent phospholipase D activation. Immunity 19,
403–412.
[65] Coutinho-Silva, R., Perfettini, J.L., Persechini, P.M., Dautry-Varsat, A. and
Ojcius, D.M. (2001) Modulation of P2Z/P2X(7) receptor activity in
macrophages infected with Chlamydia psittaci. Am. J. Physiol. Cell Physiol.
280, C81–C89.
[66] Coutinho-Silva, R. and Ojcius, D.M. (2012) Role of extracellular nucleotides in
the immune response against intracellular bacteria and protozoan parasites.
Microbes Infect. 14, 1271–1277.
[67] Eugenin, E.A. and Berman, J.W. (2013) Cytochrome c dysregulation induced
by HIV infection of astrocytes results in bystander apoptosis of uninfected
astrocytes by an IP and calcium-dependent mechanism. J. Neurochem. 127,
644–651.
[68] Eugenin, E.A., Clements, J.E., Zink, M.C. and Berman, J.W. (2011) Human
immunodeﬁciency virus infection of human astrocytes disrupts blood–brain
barrier integrity by a gap junction-dependent mechanism. J. Neurosci. 31,
9456–9465.
[69] Eugenin, E.A. and Berman, J.W. (2007) Gap junctions mediate human
immunodeﬁciency virus-bystander killing in astrocytes. J. Neurosci. 27,
12844–12850.
[70] Tran Van Nhieu, G., Clair, C., Bruzzone, R., Mesnil, M., Sansonetti, P. and
Combettes, L. (2003) Connexin-dependent inter-cellular communication
increases invasion and dissemination of Shigella in epithelial cells. Nat. Cell
Biol. 5, 720–726.
[71] Romero, S., Grompone, G., Carayol, N., Mounier, J., Guadagnini, S., Prevost,
M.C., Sansonetti, P.J. and Van Nhieu, G.T. (2011) ATP-mediated Erk1/2
activation stimulates bacterial capture by ﬁlopodia, which precedes Shigella
invasion of epithelial cells. Cell Host Microbe 9, 508–519.
[72] Kasper, C.A., Sorg, I., Schmutz, C., Tschon, T., Wischnewski, H., Kim, M.L. and
Arrieumerlou, C. (2010) Cell-cell propagation of NF-kappaB transcription
factor and MAP kinase activation ampliﬁes innate immunity against bacterial
infection. Immunity 33, 804–816.
[73] Velasquez Almonacid, L.A. et al. (2009) Role of connexin-43 hemichannels in
the pathogenesis of Yersinia enterocolitica. Vet. J. 182, 452–457.
[74] Esen, N., Shufﬁeld, D., Syed, M.M. and Kielian, T. (2007) Modulation of
connexin expression and gap junction communication in astrocytes by the
gram-positive bacterium S. aureus. Glia 55, 104–117.
[75] Karpuk, N., Burkovetskaya, M., Fritz, T., Angle, A. and Kielian, T. (2011)
Neuroinﬂammation leads to region-dependent alterations in astrocyte
gap junction communication and hemichannel activity. J. Neurosci. 31,
414–425.
[76] Robertson, J., Lang, S., Lambert, P.A. and Martin, P.E. (2010) Peptidoglycan
derived from Staphylococcus epidermidis induces Connexin43 hemichannel
activity with consequences on the innate immune response in endothelial
cells. Biochem. J. 432, 133–143.
[77] Ross, S.A., Novak, Z., Kumbla, R.A., Zhang, K., Fowler, K.B. and Boppana, S.
(2007) GJB2 and GJB6 mutations in children with congenital cytomegalovirus
infection. Pediatr. Res. 61, 687–691.
[78] Housley, G.D., Bringmann, A. and Reichenbach, A. (2009) Purinergic signaling
in special senses. Trends Neurosci. 32, 128–141.
[79] Wang, N. et al. (2013) Paracrine signaling through plasma membrane
hemichannels. Biochim. Biophys. Acta 1828, 35–50.
[80] Khan, Z., Yaiw, K.C., Wilhelmi, V., Lam, H., Rahbar, A., Stragliotto, G. and
Soderberg-Naucler, C. (2014) Human cytomegalovirus immediate early
proteins promote degradation of connexin 43 and disrupt gap junction
communication: implications for a role in gliomagenesis. Carcinogenesis 35,
145–154.
[81] Liu, X., Sun, L., Torii, M. and Rakic, P. (2012) Connexin 43 controls the
multipolar phase of neuronal migration to the cerebral cortex. Proc. Natl.
Acad. Sci. U.S.A. 109, 8280–8285.
[82] Elias, L.A., Wang, D.D. and Kriegstein, A.R. (2007) Gap junction adhesion
is necessary for radial migration in the neocortex. Nature 448,
901–907.
[83] Liu, X., Hashimoto-Torii, K., Torii, M., Ding, C. and Rakic, P. (2010) Gap
junctions/hemichannels modulate interkinetic nuclear migration in the
forebrain precursors. J. Neurosci. 30, 4197–4209.
[84] Hsiao, H.J., Liu, P.A., Yeh, H.I. andWang, C.Y. (2010) Classical swine fever virus
down-regulates endothelial connexin 43 gap junctions. Arch. Virol. 155,
1107–1116.
[85] Koster-Patzlaff, C., Hosseini, S.M. and Reuss, B. (2007) Persistent Borna
Disease Virus infection changes expression and function of astroglial gap
junctions in vivo and in vitro. Brain Res. 1184, 316–332.
[86] Koster-Patzlaff, C., Hosseini, S.M. and Reuss, B. (2008) Layer speciﬁc changes
of astroglial gap junctions in the rat cerebellar cortex by persistent Borna
Disease Virus infection. Brain Res. 1219, 143–158.
[87] Koster-Patzlaff, C., Hosseini, S.M. and Reuss, B. (2009) Loss of connexin36 in
rat hippocampus and cerebellar cortex in persistent Borna disease virus
infection. J. Chem. Neuroanat. 37, 118–127.
[88] Fatemi, S.H., Folsom, T.D., Reutiman, T.J. and Sidwell, R.W. (2008) Viral
regulation of aquaporin 4, connexin 43, microcephalin and nucleolin.
Schizophr Res. 98, 163–177.
[89] Musee, J., Mbuy, G.N. and Woodruff, R.I. (2002) Antiviral agents alter ability
of HSV-2 to disrupt gap junctional intercellular communication between
mammalian cells in vitro. Antiviral Res. 56, 143–151.
E.A. Eugenin / FEBS Letters 588 (2014) 1389–1395 1395[90] Fischer, N.O., Mbuy, G.N. and Woodruff, R.I. (2001) HSV-2 disrupts gap
junctional intercellular communication between mammalian cells in vitro. J.
Virol. Methods 91, 157–166.
[91] Knabb, M.T., Danielsen, C.A., McShane-Kay, K., Mbuy, G.K. and Woodruff, R.I.
(2007) Herpes simplex virus-type 2 infectivity and agents that block gap
junctional intercellular communication. Virus Res. 124, 212–219.
[92] Crow, D.S., Beyer, E.C., Paul, D.L., Kobe, S.S. and Lau, A.F. (1990)
Phosphorylation of connexin43 gap junction protein in uninfected and
Rous sarcoma virus-transformed mammalian ﬁbroblasts. Mol. Cell Biol. 10,
1754–1763.
[93] Crow, D.S., Kurata, W.E. and Lau, A.F. (1992) Phosphorylation of connexin43
in cells containing mutant src oncogenes. Oncogene 7, 999–1003.
[94] Filson, A.J., Azarnia, R., Beyer, E.C., Loewenstein, W.R. and Brugge, J.S. (1990)
Tyrosine phosphorylation of a gap junction protein correlates with inhibition
of cell-to-cell communication. Cell Growth Differ. 1, 661–668.
[95] Ashraﬁ, G.H., Pitts, J.D., Faccini, A., McLean, P., O’Brien, V., Finbow, M.E. and
Campo, S. (2000) Binding of bovine papillomavirus type 4 E8 to ductin (16K
proteolipid), down-regulation of gap junction intercellular communication
and full cell transformation are independent events. J. Gen. Virol. 81, 689–694.
[96] Faccini, A.M., Cairney, M., Ashraﬁ, G.H., Finbow, M.E., Campo, M.S. and Pitts,
J.D. (1996) The bovine papillomavirus type 4 E8 protein binds to ductin and
causes loss of gap junctional intercellular communication in primary
ﬁbroblasts. J. Virol. 70, 9041–9045.
[97] Cosenza, M.A., Zhao, M.L., Si, Q. and Lee, S.C. (2002) Human brain
parenchymal microglia express CD14 and CD45 and are productively
infected by HIV-1 in HIV-1 encephalitis. Brain Pathol. 12, 442–455.
[98] Wiley, C.A., Schrier, R.D., Nelson, J.A., Lampert, P.W. and Oldstone, M.B. (1986)
Cellular localization of human immunodeﬁciency virus infection within the
brains of acquired immune deﬁciency syndrome patients. Proc. Natl. Acad.
Sci. U.S.A. 83, 7089–7093.
[99] Conant, K., Tornatore, C., Atwood, W., Meyers, K., Traub, R. and Major, E.O.
(1994) In vivo and in vitro infection of the astrocyte by HIV-1. Adv.
Neuroimmunol. 4, 287–289.
[100] Eugenin, E.A. and Berman, J.W. (2007) Gap junctions mediate human
immunodeﬁciency virus-bystander killing in astrocytes. J. Neurosci. 27,
12844–12850.
[101] Ohagen, A. et al. (1999) Apoptosis induced by infection of primary brain
cultures with diverse human immunodeﬁciency virus type 1 isolates:
evidence for a role of the envelope. J. Virol. 73, 897–906.
[102] Tornatore, C., Chandra, R., Berger, J.R. and Major, E.O. (1994) HIV-1 infection
of subcortical astrocytes in the pediatric central nervous system. Neurology
44, 481–487.
[103] Bagasra, O., Lavi, E., Bobroski, L., Khalili, K., Pestaner, J.P., Tawadros, R. and
Pomerantz, R.J. (1996) Cellular reservoirs of HIV-1 in the central nervous
system of infected individuals: identiﬁcation by the combination of in situ
polymerase chain reaction and immunohistochemistry. AIDS 10, 573–585.[104] Nuovo, G.J., Gallery, F., MacConnell, P. and Braun, A. (1994) In situ detection
of polymerase chain reaction-ampliﬁed HIV-1 nucleic acids and tumor
necrosis factor-alpha RNA in the central nervous system. Am. J. Pathol. 144,
659–666.
[105] Takahashi, K., Wesselingh, S.L., Grifﬁn, D.E., McArthur, J.C., Johnson, R.T. and
Glass, J.D. (1996) Localization of HIV-1 in human brain using polymerase
chain reaction/in situ hybridization and immunocytochemistry. Ann. Neurol.
39, 705–711.
[106] Churchill, M.J., Wesselingh, S.L., Cowley, D., Pardo, C.A., McArthur, J.C., Brew,
B.J. and Gorry, P.R. (2009) Extensive astrocyte infection is prominent in
human immunodeﬁciency virus-associated dementia. Ann. Neurol. 66, 253–
258.
[107] Eugenin, E.A., Clements, J.E., Zink, M.C. and Berman, J.W. (2011) Human
immunodeﬁciency virus infection of human astrocytes disrupts blood–brain
barrier integrity by a gap junction-dependent mechanism. J. Neurosci. 31,
9456–9465.
[108] Eugenin, E.A., King, J.E., Hazleton, J.E., Major, E.O., Bennett, M.V., Zukin, R.S.
and Berman, J.W. (2011) Differences in NMDA receptor expression during
human development determine the response of neurons to HIV-tat-mediated
neurotoxicity. Neurotox. Res. 19, 138–148.
[109] Orellana, J.A., Saez, J.C., Bennett, M.V., Berman, J.W., Morgello, S. and Eugenin,
E.A. (2014) HIV increases the release of dickkopf-1 protein from human
astrocytes by a Cx43 hemichannel-dependent mechanism. J. Neurochem.. in
press.
[110] Li, W., Henderson, L.J., Major, E.O. and Al-Harthi, L. (2011) IFN-gamma
mediates enhancement of HIV replication in astrocytes by inducing an
antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent
manner. J. Immunol. 186, 6771–6778.
[111] Seror, C. et al. (2011) Extracellular ATP acts on P2Y2 purinergic receptors to
facilitate HIV-1 infection. J. Exp. Med. 208, 1823–1834.
[112] Orellana, J.A., Velasquez, S., Williams, D.W., Saez, J.C., Berman, J.W. and
Eugenin, E.A. (2013) Pannexin1 hemichannels are critical for HIV infection of
human primary CD4+ T lymphocytes. J. Leukocyte Biol. 94, 399–407.
[113] Hazleton, J.E., Berman, J.W. and Eugenin, E.A. (2012) Purinergic receptors are
required for HIV-1 infection of primary human macrophages. J. Immunol.
188, 4488–4495.
[114] Pingle, S.C. et al. (2007) Activation of the adenosine A1 receptor inhibits HIV-
1 tat-induced apoptosis by reducing nuclear factor-kappaB activation and
inducible nitric-oxide synthase. Mol. Pharmacol. 72, 856–867.
[115] Fotheringham, J., Mayne, M., Holden, C., Nath, A. and Geiger, J.D. (2004)
Adenosine receptors control HIV-1 Tat-induced inﬂammatory responses
through protein phosphatase. Virology 327, 186–195.
[116] By, Y., Durand-Gorde, J.M., Condo, J., Lejeune, P.J., Fenouillet, E., Guieu, R. and
Ruf, J. (2010) Monoclonal antibody-assisted stimulation of adenosine A2A
receptors induces simultaneous downregulation of CXCR4 and CCR5 on CD4+
T-cells. Hum. Immunol. 71, 1073–1076.
